IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States and Europe. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations without the need for highly specialized informatics professionals, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut.
IPO Year: 2021
Exchange: NASDAQ
Website: isoplexis.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/15/2022 | $17.00 → $12.00 | Overweight | Morgan Stanley |
| 1/27/2022 | $20.00 → $15.00 | Outperform | SVB Leerink |
| 11/19/2021 | $24.00 | Outperform | Evercore ISI Group |
| 11/11/2021 | $17.00 → $20.00 | Outperform | SVB Leerink |
| 11/2/2021 | $17.00 | Outperform | SVB Leerink |
| 11/2/2021 | Outperform | Cowen & Co. | |
| 11/2/2021 | $16.00 | Overweight | Morgan Stanley |
BRANFORD, Conn., Nov. 30, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ: ISO), the leader in functional single-cell proteomics, today announced the appointment of Richard Rew as Senior VP, General Counsel and Secretary; Raj Khakhar as VP of Finance; and Manny Resendes as Global Controller. These three new appointments further strengthen Isoplexis' financial and legal teams. "We are excited to have Mr. Rew, Mr. Khakhar, and Mr. Resendes join our team at IsoPlexis," said Sean Mackay, CEO of IsoPlexis. "These recent hires will strengthen our ability to accelerate our growth trajectory a
BRANFORD, Conn., Nov. 12, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ:ISO), the leader in functional single-cell proteomics, today announced the appointment of two new leadership positions at the company. Michelle Reid, Ph.D. joins IsoPlexis as VP of Service and Support, and Anthony Catalano joins as the Senior VP of Operations. With these appointments, IsoPlexis continues to strengthen its operations and product support teams, providing high need proteomic products with highly customer centric support. Ms. Reid comes to IsoPlexis with over 20 years of experience leading and devel
BRANFORD, Conn., Nov. 12, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ:ISO), the leader in functional single-cell proteomics, today announced the appointment of two new leadership positions at the company. Michelle Reid, Ph.D. joins IsoPlexis as VP of Service and Support, and Anthony Catalano joins as the Senior VP of Operations. With these appointments, IsoPlexis continues to strengthen its operations and product support teams, providing high need proteomic products with highly customer centric support. Ms. Reid comes to IsoPlexis with over 20 years of experience leading and devel
15-12G - IsoPlexis Corp (0001615055) (Filer)
8-K - IsoPlexis Corp (0001615055) (Filer)
S-8 POS - IsoPlexis Corp (0001615055) (Filer)
S-8 POS - IsoPlexis Corp (0001615055) (Filer)
25-NSE - IsoPlexis Corp (0001615055) (Subject)
425 - IsoPlexis Corp (0001615055) (Subject)
8-K - IsoPlexis Corp (0001615055) (Filer)
DEFA14A - IsoPlexis Corp (0001615055) (Filer)
425 - IsoPlexis Corp (0001615055) (Subject)
8-K - IsoPlexis Corp (0001615055) (Filer)
4 - IsoPlexis Corp (0001615055) (Issuer)
4 - IsoPlexis Corp (0001615055) (Issuer)
4 - IsoPlexis Corp (0001615055) (Issuer)
4 - IsoPlexis Corp (0001615055) (Issuer)
4 - IsoPlexis Corp (0001615055) (Issuer)
4 - IsoPlexis Corp (0001615055) (Issuer)
4 - IsoPlexis Corp (0001615055) (Issuer)
4 - IsoPlexis Corp (0001615055) (Issuer)
4 - IsoPlexis Corp (0001615055) (Issuer)
4 - IsoPlexis Corp (0001615055) (Issuer)
Morgan Stanley reiterated coverage of IsoPlexis with a rating of Overweight and set a new price target of $12.00 from $17.00 previously
SVB Leerink reiterated coverage of IsoPlexis with a rating of Outperform and set a new price target of $15.00 from $20.00 previously
Evercore ISI Group initiated coverage of IsoPlexis with a rating of Outperform and set a new price target of $24.00
SVB Leerink reiterated coverage of IsoPlexis with a rating of Outperform and set a new price target of $20.00 from $17.00 previously
SVB Leerink initiated coverage of IsoPlexis with a rating of Outperform and set a new price target of $17.00
Cowen & Co. initiated coverage of IsoPlexis with a rating of Outperform
Morgan Stanley initiated coverage of IsoPlexis with a rating of Overweight and set a new price target of $16.00
Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expected as a Standalone Entity Companies to Host Joint Conference Call and Webcast Today at 5:00 p.m. ET EMERYVILLE, CA and BRANFORD, Conn., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights (NASDAQ:BLI), a life sciences tools company, and IsoPlexis (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a definitive agreement under which Berkeley Lights will acquire
Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expected as a Standalone Entity Companies to Host Joint Conference Call and Webcast Today at 5:00 p.m. ET EMERYVILLE, Calif. and BRANFORD, Conn., Dec. 21, 2022 /PRNewswire/ -- Berkeley Lights (NASDAQ:BLI), a life sciences tools company, and IsoPlexis (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a definitive agreement under which Berkeley Lights will acquire IsoP
BRANFORD, Conn., Oct. 19, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will report financial results for the third quarter 2022 before market open on Thursday, November 10, 2022. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.isoplexis.com. The webcast will be archived and available for replay after the event. About IsoPlexis IsoPlexis is empowering labs to leverage the ce
BRANFORD, Conn., July 21, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO), the Superhuman Cell Company, today announced it will report financial results for the second quarter 2022 before market open on Wednesday, August 10, 2022. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.isoplexis.com. The webcast will be archived and available for replay after the event. About IsoPlexisIsoPlexis is the Superhuman Cell company. By leading the discovery and identification of how multi-functional immune—
BRANFORD, Conn., Feb. 16, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO), the Superhuman Cell Company, today announced it will report financial results for the fourth quarter and full year 2021 before market open on Wednesday, March 2, 2022. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.isoplexis.com. The webcast will be archived and available for replay after the event. About IsoPlexisIsoPlexis is the Superhuman Cell company. IsoPlexis' systems uniquely identify a comprehensive range of m
BRANFORD, Conn., Oct. 26, 2021 /PRNewswire/ -- IsoPlexis Corporation (NASDAQ:ISO), a leader in functional single-cell proteomics, today announced it will report financial results for the third quarter 2021 before market open on Wednesday, November 10, 2021. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.isoplexis.com. The webcast will be archived and available for replay after the event. Abo
PhenomeX to begin trading under symbol (NASDAQ:CELL) EMERYVILLE, Calif., March 21, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today announced that it has completed its previously announced acquisition of IsoPlexis Corporation (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health. The newly combined company has been renamed PhenomeX and its common stock will begin trading on Nasdaq under the ticker symbol "CELL" at market open tomorrow. PhenomeX is positioned to be the leading
BRANFORD, Conn., Jan. 12, 2023 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced its preliminary unaudited revenue for the full year ended December 31, 2022. Total revenue for the full year ended December 31, 2022 is expected to be in the range of $16.6 to $16.8 million, representing a decrease of approximately 3% to 4% compared to $17.3 million for the full year ended December 31, 2021. Fourth quarter results were lower than expected primarily due to the timing of customer orders for instruments and lower consumable sales, as the previously described macroeconomic head
Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expected as a Standalone Entity Companies to Host Joint Conference Call and Webcast Today at 5:00 p.m. ET EMERYVILLE, CA and BRANFORD, Conn., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights (NASDAQ:BLI), a life sciences tools company, and IsoPlexis (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a definitive agreement under which Berkeley Lights will acquire
Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expected as a Standalone Entity Companies to Host Joint Conference Call and Webcast Today at 5:00 p.m. ET EMERYVILLE, Calif. and BRANFORD, Conn., Dec. 21, 2022 /PRNewswire/ -- Berkeley Lights (NASDAQ:BLI), a life sciences tools company, and IsoPlexis (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a definitive agreement under which Berkeley Lights will acquire IsoP
BRANFORD, Conn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today reported financial results for the quarter ended September 30, 2022. Recent Highlights Revenue of $4.5 million for the third quarter 2022, representing a 7% increase from the corresponding period of 2021Sold 23 new instruments in the third quarter, bringing cumulative instruments sold to 277Reduced total operating expenses by 27% from the prior quarter and 37% from Q1, due to continued efforts to streamline operations and enhance productivityPartnered with MediMergent and The Center for Cancer and Bl
BRANFORD, Conn., Nov. 09, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will be participating in the following investor conferences. Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, New York, NYMulti-Omics Panel on Thursday, November 17th at 1:00 p.m. Eastern Time / 10:00 a.m. Pacific Time Evercore ISI HealthCONx Conference, VirtualFireside Chat on Thursday, December 1st at 12:10 p.m. Eastern Time / 9:10 a.m. Pacific Time A live webcast and replay of the Evercore ISI HealthCONx Conference fireside chat will be available on the "In
BRANFORD, Conn., Oct. 19, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will report financial results for the third quarter 2022 before market open on Thursday, November 10, 2022. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.isoplexis.com. The webcast will be archived and available for replay after the event. About IsoPlexis IsoPlexis is empowering labs to leverage the ce
BRANFORD, Conn., Sept. 13, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO) ("IsoPlexis"), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced the publication of initial data off its CodePlex platform in the journal Scientific Reports carried out by researchers at the Shanghai Institute of Hematology. With the recent establishment of a regional headquarters in Shanghai, IsoPlexis has strengthened its capability to support and equip customers in the APAC region, enabling groundbreaking innovation. In the paper titled "Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence again
BRANFORD, Conn., Sept. 06, 2022 (GLOBE NEWSWIRE) -- IsoPlexis (NASDAQ: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a partnership with MediMergent, LLC, and The Center for Cancer and Blood Disorders (CCBD), an American Oncology Partners of Maryland practice, to leverage IsoPlexis' single-cell proteomics in a large multi-site study of immuno-compromised cancer patients. The study entitled "Real World Evaluation of the Effectiveness of AZD7442 for Prevention of COVID-19 Infection in Immuno-Suppressed Cancer Patients", will focus on immune cells' functionality and their role in prevention of COVID-19 breakthrough infec
BRANFORD, Conn., Aug. 31, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO) ("IsoPlexis"), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will be participating in the upcoming Morgan Stanley Global Healthcare Conference in New York, NY. IsoPlexis' management is scheduled to participate in a fireside chat on Monday, September 12th at 4:50 p.m. Eastern Time / 1:50 p.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: www.isoplexis.com. About IsoPlexis IsoPlexis is empowering labs, changing the course of human heal
SC 13D/A - IsoPlexis Corp (0001615055) (Subject)
SC 13G/A - IsoPlexis Corp (0001615055) (Subject)
SC 13G/A - IsoPlexis Corp (0001615055) (Subject)
SC 13G/A - IsoPlexis Corp (0001615055) (Subject)
SC 13G/A - IsoPlexis Corp (0001615055) (Subject)
SC 13G/A - IsoPlexis Corp (0001615055) (Subject)
SC 13G/A - IsoPlexis Corp (0001615055) (Subject)
SC 13D/A - IsoPlexis Corp (0001615055) (Subject)
SC 13G/A - IsoPlexis Corp (0001615055) (Subject)
SC 13G - IsoPlexis Corp (0001615055) (Subject)
Gainers Catalyst Biosciences (NASDAQ:CBIO) shares moved upwards by 59.1% to $0.38 during Tuesday's pre-market session. The market value of their outstanding shares is at $14.4 million. eFFECTOR Therapeutics (NASDAQ:EFTR) stock moved upwards by 34.04% to $0.65. The company's market cap stands at $27.2 million. Stereotaxis (AMEX:STXS) stock increased by 28.85% to $3.26. The company's market cap stands at $243.9 million. Cardio Diagnostics Hldgs (NASDAQ:CDIO) stock increased by 26.61% to $1.69. The market value of their outstanding shares is at $16.0 million. Adamis Pharmaceuticals (NASDAQ:ADMP) stock moved upwards by 22.73% to $0.32. The company's market cap stands at $48.5 million. Come
IsoPlexis Corporation (NASDAQ: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced its preliminary unaudited revenue for the full year ended December 31, 2022. Total revenue for the full year ended December 31, 2022 is expected to be in the range of $16.6 to $16.8 million, representing a decrease of approximately 3% to 4% compared to $17.3 million for the full year ended December 31, 2021. Fourth quarter results were lower than expected primarily due to the timing of customer orders for instruments and lower consumable sales, as the previously described macroeconomic headwinds and difficult international environment persi
Gainers Sotera Health Company (NASDAQ:SHC) shares jumped 92% to $16.59 after the company announced its subsidiaries have reached agreements to settle the Ethylene Oxide cases pending against Sterigenics. Sterigenics will pay the company $408 million to settle the claims. Party City Holdco Inc. (NYSE:PRTY) gained 54% to $0.3193 following an Axios report suggesting The Franchise Group could be looking at acquiring the company. Panbela Therapeutics, Inc. (NASDAQ:PBLA) shares rose 51.1% to $0.1224 after gaining 4% on Monday. VYNE Therapeutics Inc. (NASDAQ:VYNE) climbed 50.5% to $0.2892 after the company announced the first vitiligo patient was dosed in a Phase 1a/b clinical trial of VYN201
https://ppubs.uspto.gov/pubwebapp/
Gainers VYNE Therapeutics (NASDAQ:VYNE) shares rose 87.0% to $0.36 during Monday's after-market session. At the close, VYNE Therapeutics's trading volume reached 2.9 million shares. This is 590.3% of its average volume over the last 100 days. The company's market cap stands at $20.8 million. Clearside Biomedical (NASDAQ:CLSD) stock increased by 12.41% to $1.81. The market value of their outstanding shares is at $108.9 million. Nuwellis (NASDAQ:NUWE) shares increased by 12.01% to $10.44. Nuwellis's trading volume hit 230.9K shares by close, accounting for 92.9% of its average volume over the last 100 days. The market value of their outstanding shares is at $5.5 million. First Wave BioPhar
Morgan Stanley has decided to maintain its Equal-Weight rating of IsoPlexis (NASDAQ:ISO) and lower its price target from $5.00 to $1.70. Shares of IsoPlexis are trading down 3.13% over the last 24 hours, at $1.55 per share. A move to $1.70 would account for a 9.68% increase from the current share price. About IsoPlexis IsoPlexis Corp is a developer of a single-cell detection system designed to accelerate insights in the field of cancer. It designed a platform to reveal functional protein biology and cellular signaling networks at single-cell resolution to accelerate the development of advanced medicines. About Analyst Ratings Analysts work in banking and financial systems and typically speci
Morgan Stanley analyst Tejas Savant maintains IsoPlexis (NASDAQ:ISO) with a Equal-Weight and lowers the price target from $5 to $1.7.
Gainers Quotient Limited (NASDAQ:QTNT) shares rose 125% to $0.54 in pre-market trading after dropping around 38% on Wednesday. Quotient recently announced the intent to voluntary delist from the Nasdaq Global Market. Esports Entertainment Group, Inc. (NASDAQ:GMBL) rose 62.2% to $0.1281 in pre-market trading after declining over 10% on Wednesday. Esports Entertainment Group recently named Alex Igelman as Chief Executive Officer. Baudax Bio, Inc. (NASDAQ:BXRX) shares rose 37.4% to $3.16 in pre-market trading after gaining over 5% on Wednesday. Baudax Bio recently announced initiation of a Phase II clinical trial evaluationg BX1000 in patients undergoing surgery. AEye, Inc. (NASDAQ:LIDR
Gainers NexImmune (NASDAQ:NEXI) shares increased by 15.4% to $0.28 during Friday's after-market session. The market value of their outstanding shares is at $7.3 million. Lipocine (NASDAQ:LPCN) stock rose 9.72% to $0.44. The market value of their outstanding shares is at $38.9 million. Tenax Therapeutics (NASDAQ:TENX) shares increased by 8.69% to $0.12. The market value of their outstanding shares is at $5.5 million. Precipio (NASDAQ:PRPO) shares moved upwards by 8.59% to $0.6. The market value of their outstanding shares is at $13.6 million. Exicure (NASDAQ:XCUR) shares increased by 8.59% to $1.39. Exicure's trading volume hit 375.9K shares by close, accounting for 192.4% of its average
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping over 600 points on Thursday. The Dow traded down 1.84% to 32,761.20 while the NASDAQ fell 3% to 10,389. The S&P 500 also fell, dropping, 2.33% to 3,787.90. Check This Out: Market Volatility Drops Further Following Rebound In US Consumer Confidence Leading and Lagging Sectors Consumer staples shares fell by just 0.9% on Thursday. Meanwhile, top gainers in the sector included Calavo Growers, Inc. (NASDAQ:CVGW), up 3%, and Whole Earth Brands, Inc. (NASDAQ:FREE), up 3%. In trading on Thursday, information technology shares dipped by 3.7%. Top Headline The US economy expanded an annualized 3.2% on q